oral glp 1 agonist brand name America's Poison Centers Novo Nordisk's oral GLP-1 drug

For patients with established HF and a reduced left ventricular ejection fraction (LVEF), the LIVE and FIGHT trials studied the effect of 2-year liraglutide use [90, 91]

Moreover, even when prescribed, Hispanic and non-Hispanic Black individuals are more likely to report cost-prohibitive access barriers to diabetes medications, increasing risk in these populations for diabetes-related complications and mortality.[85] As future research aims to comprehensively assess the full scope of GLP-1RAs benefits and risks, it is imperative that such studies include the populations with the greatest potential for benefit and explore strategies to mitigate disparities in post-marketing access to these therapies.[86] CONCLUSIONS Since their introduction two decades ago, GLP-1RAs have expanded from glycemic control to treat a variety of conditions in individuals without diabetes, including weight management, cardiovascular risk reduction, and obstructive sleep apnea

Pfeifer, K

Given the continued growth of the obesity epidemic, primary care providers should prescribing GLPs for patients with nondiabetic obesity

Preclinical studies have validated the therapeutic potential of these compounds for the treatment of obesity and diabetes

You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion